ArticleAntibiotics (Basel, Switzerland)2024
Decline in ESBL Production and Carbapenem Resistance in Urinary Tract Infections among Key Bacterial Species during the COVID-19 Pandemic.
Article in Antibiotics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 11 citations in OpenAlex.
- Epidemiology of Urinary Pathogens and Antibiotic Resistance Trends: A Retrospective Analysis Stratified by Age and Sex from a Large Tertiary Hospital in Saudi Arabia.Infection and drug resistance · 2026Article
- Antimicrobial Resistance in Urinary Tract Infections Among Patients with and Without Renal Comorbidities: A Retrospective Study from Al-Baha, Saudi Arabia.Pathogens (Basel, Switzerland) · 2025Article
- Antimicrobial Resistance Trends, Resistance Mechanisms, and Antibiotic Consumption in COVID-19 Versus Non-COVID-19 Units: A Seven-Year Retrospective Cohort Study.Antibiotics (Basel, Switzerland) · 2025Article
- Risk Factors and Clinical Impact of Extended-Spectrum Beta-Lactamase (ESBL)-ProducingAntibiotics (Basel, Switzerland) · 2025Article
- Challenges in the Treatment of Urinary Tract Infections: Antibiotic Resistance Profiles ofBiomedicines · 2025Article
- Epidemiological and Antimicrobial Resistance Trends ofInfection and drug resistance · 2025Article
- The challenge of multidrug resistance in hospitalized pediatric patients with urinary tract infections.Frontiers in cellular and infection microbiology · 2025Article
- Antimicrobial Susceptibility Trends inPathogens (Basel, Switzerland) · 2024Article
- Article
- Prevalence, Risk Factors and Antibiotic Resistance of Extended-Spectrum Beta-Lactamase-ProducingChildren (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic has led to significant changes in healthcare practices, including increased antibiotic usage. This study aimed to investigate the impact of the pandemic on the prevalence of extended-spectrum β-lactamase (ESBL) production and carbapenem resistance among key bacterial species causing urinary tract infections (UTIs). Conducted at King Fahad Medical City in Riyadh from January 2018 to December 2022, the study analyzed urine samples from 9697 UTI patients. Patients were categorized into 'pre-COVID-19' and 'during COVID-19' groups. Bacterial isolates were identified, and antimicrobial susceptibility testing was performed following guidelines. ESBL production was detected using the Double-Disc Synergy Test.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.